PPCB: PPCB: Published pilot study shows PRP cuts pancreatic tumor weight ~86% in mice and shows supportive patient survival signal

AI Summary

Propanc published a peer-reviewed pilot study reporting that its PRP proenzyme (trypsinogen:chymotrypsinogen A, 1:6) showed synergistic growth inhibition across 24 cancer cell lines and produced an 85.9% reduction in mean tumor weight in a syngeneic orthotopic pancreatic (Pan02) mouse model and ~50% inhibition in an orthotopic ovarian model, with evidence of anti-angiogenic, anti‑metastatic and EMT‑reversal activity. The paper also reports an observational UK Specials cohort (n=46) treated with a rectal proenzyme formulation where mean survival was 9.0 months versus an expected 5.6 months (p<0.05) and no severe treatment‑related adverse events were observed. These are pilot, preclinical and non‑randomized observational findings (and include different routes/formulations between animal IV dosing and the UK rectal use) that will need controlled clinical trials for confirmation.

Positives

85.9% mean tumor weight reduction in syngeneic orthotopic pancreatic (Pan02) mouse model at higher PRP dose
PRP showed dose-dependent anti-angiogenic, anti-metastatic and EMT-reversal activity and synergy across 24 human cancer cell lines
Observational UK cohort (n=46) reported mean survival 9.0 vs expected 5.6 months (p<0.05) with no severe treatment-related adverse events

Negatives

Data are from a pilot preclinical study and a small, non-randomized observational patient cohort, not from controlled clinical trials
Animal efficacy used daily IV PRP while the UK patient data used a rectal proenzyme formulation — different routes/formulations
Early results require controlled clinical studies to validate efficacy, dosing and safety in humans